Virus Or Bacteriophage, Except For Viral Vector Or Bacteriophage Vector; Composition Thereof; Preparation Or Purification Thereof; Production Of Viral Subunits; Media For Propagating Patents (Class 435/235.1)
-
Patent number: 11242504Abstract: We have modified a commercially-available adherent cell culture bioreactor, developing a new sampling manifold configuration and new way of taking samples to reduce contamination risk.Type: GrantFiled: March 19, 2019Date of Patent: February 8, 2022Assignee: Trizell Ltd.Inventors: Piia Kristiina Valonen, Eva Kristiina Rasanen, Tarja Hannele Tuunanen, Milla Jonna Karoliina Karnaattu, Achim Muller, Minna Kristiina Karhinen, Seppo Yla-Herttuala
-
Patent number: 11219901Abstract: The invention concerns a robotic method for coating the bottom surface of at least one well of a multiwell plate by a polyelectrolyte multilayer film, the multiwell plate obtainable according to the method and the use thereof for cell culture.Type: GrantFiled: December 15, 2017Date of Patent: January 11, 2022Assignees: INSTITUT POLYTECHNIQUE DE GRENOBLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Catherine Cécile Picart, Jie Liu, Fabien Dalonneau, Paul Machillot
-
Patent number: 11208630Abstract: Provided herein are methods of improving rAAV production in cells, the method comprising increasing the salt concentration in the media in which the cells are infected or transfected, cultured, or in which they produce AAV. Aspects of the disclosure relate to improved methods of rAAV production by co-infecting suspension adapted cells (e.g., suspension adapted HEK293 cells) with viruses that encode one or more AAV components for producing rAAV particles within the suspension adapted cells.Type: GrantFiled: December 23, 2016Date of Patent: December 28, 2021Assignee: University of Florida Research Foundation, IncorporatedInventors: Nathalie Clement, Barry John Byrne, Laura A. Small
-
Patent number: 11191733Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at ?5 to 50° C. to introduce the drug into the empty capsid or the empty particle.Type: GrantFiled: February 28, 2017Date of Patent: December 7, 2021Assignee: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Takashi Okada, Shin'ichi Takeda, Hiromi Kinoh
-
Patent number: 11191826Abstract: This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.Type: GrantFiled: April 4, 2018Date of Patent: December 7, 2021Assignee: Mayo Foundation for Medical Education and ResearchInventors: Miguel A. Munoz Alia, Stephen James Russell
-
Patent number: 11193931Abstract: A VAMP epitope suitable for generating an antibody against a VAMP C-terminal neurotoxin cleavage product. Method of using such an epitope to generate an antibody against cleaved VAMP. Method of using such an antibody to assay for cleavage of a VAMP by clostridial neurotoxin.Type: GrantFiled: October 18, 2017Date of Patent: December 7, 2021Assignee: IPSEN BIOPHARM LIMITEDInventors: Bryony Gray, Verity Cadd, Matthew Beard
-
Patent number: 11193111Abstract: Virus particle multimers and methods of making and using such virus particle multimer are described. Virus particle multimers are constructed by preparing a plurality of asymmetrically functionalized virus particles bearing one or more functional groups and contacting the asymmetrically functionalized virus particles with a first linker molecule that reacts with the functional groups to form a virus particle multimer that includes a plurality of asymmetrically functionalized virus particles connected by the linker molecule. The asymmetrically functionalized virus particles are typically prepared by attaching the virus particles to a support surface to allow asymmetrical functionalization to be introduced.Type: GrantFiled: December 27, 2013Date of Patent: December 7, 2021Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Nicole F. Steinmetz, Amy M. Wen
-
Patent number: 11124546Abstract: This invention relates to modified parvovirus capsid proteins with enhanced transduction efficiency, viral vectors comprising the same, and methods of using the same for delivery of nucleic acids to a cell or a subject.Type: GrantFiled: December 14, 2016Date of Patent: September 21, 2021Assignee: The University of North Carolina at Chapel HillInventors: Richard Jude Samulski, Jayme Warischalk
-
Patent number: 11119103Abstract: Provided herein is a test system comprising severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen, SARS-CoV-2 S2 antigen, and binding moieties that specifically bind to human IgG, human IgA, and human IgM. Also provided are methods of detecting SARS-CoV-2 antibodies in a sample using the test system.Type: GrantFiled: June 12, 2020Date of Patent: September 14, 2021Assignee: Arizona Board of Regents on Behalf of the University of Arizona, a body corporateInventors: Deepta Bhattacharya, Ryan Sprissler, Janko Nikolich-Zugich, Matthew Kaplan, Tyler Ripperger, Jennifer Uhrlaub, Makiko Watanabe, Rachel Wong
-
Patent number: 11110138Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.Type: GrantFiled: December 20, 2013Date of Patent: September 7, 2021Assignee: CELVERUM INC.Inventors: David Conrad, Cory Batenchuk, Fabrice Leboeuf, John Cameron Bell
-
Patent number: 11103570Abstract: The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against FMDV infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a FMDV protein. The invention also relates to products, methods and uses thereof, e.g., suitable to induce a protective immune response in a subject.Type: GrantFiled: June 15, 2016Date of Patent: August 31, 2021Assignee: Bavarian Nordic A/SInventors: Robin Steigerwald, Markus Kalla
-
Patent number: 11034946Abstract: A engineered alpha-galactosidase A polypeptide comprising SEQ ID NO: 1 having at least one non-glycosylation mutation; and at least one glycosylation compensatory mutation is claimed.Type: GrantFiled: October 5, 2018Date of Patent: June 15, 2021Assignee: Research Foundation of The City University of New YorkInventors: David H. Calhoun, Erin S. Stokes, M. Lane Gilchrist
-
Patent number: 11034931Abstract: The invention relates to yeast cells with useful characteristics, including being capable of utilizing panose as sole carbon source and/or capable of utilizing one or more dipeptidesas sole nitrogen source. The invention also relates to yeast cells with useful genotypes including comprising at least 4 allelic genes encoding IMA1p and/or at least two allelic genes encoding IMA5p.Type: GrantFiled: December 22, 2015Date of Patent: June 15, 2021Assignee: Carlsberg Breweries A/SInventors: Natalia Y. Solodovnikova, Jeppe Frank Andersen, Rosa Garcia Sanchez, Zoran Gojkovic
-
Patent number: 11000560Abstract: The present invention relates to oncolytic adenoviruses with functional deletions of immunodominant T-cell epitopes of adenovirus proteins, as well as to methods of using the oncolytic adenoviruses for the treatment of diseases, such as cancer. The oncolytic adenoviruses may also contain one or more heterologous nucleic acid sequences each encoding a tumor antigen or epitope. The oncolytic adenoviruses may also contain other mutations and insertions of DNA sequences used to confer selectivity and antitumor potency. The invention has application in the field of cancer therapy.Type: GrantFiled: May 4, 2016Date of Patent: May 11, 2021Assignee: VCN BIOSCIENCES, S.L.Inventors: Ramon Alemany, Raul Gil, Miriam Bazan
-
Patent number: 10994028Abstract: Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.Type: GrantFiled: September 8, 2017Date of Patent: May 4, 2021Assignee: The Children's Hospital of PhiladelphiaInventors: Guang Qu, John Fraser Wright
-
Patent number: 10975138Abstract: Production of etanercept using perfusion methods achieves attractive yields of properly folded protein. Desired temperature, feed media, titers and percent correctly folded protein are disclosed.Type: GrantFiled: June 30, 2015Date of Patent: April 13, 2021Assignee: Coherus BioSciences, Inc.Inventors: Ela Puchacz, James Russell Grove
-
Patent number: 10975425Abstract: A novel assay and a suite of devices may isolate nucleic acids from prokaryotic and eukaryotic cells and prepare samples for real-time (quantitative) polymerase chain reaction (PCR) analysis. The assay may employ an aqueous-based non-alcohol approach that yields robust RNA quality. The suite of ready-to-use devices may provide pre-loaded reagents in liquid and lyophilized formats to enable rapid manual operation in a laboratory or remote field environments. The assay and devices may be particularly suitable to analysis in microgravity or deep space environments.Type: GrantFiled: August 28, 2017Date of Patent: April 13, 2021Assignee: United States of America as Represented by the Administrator of NASAInventors: Travis David Boone, Jimmy Kar Chuen Jung, Macarena Parra, Mark Brown
-
Patent number: 10928383Abstract: A method for predicting an effect of a medication or a treatment regimen to a subject suffering from a cancer, the method comprises: (A) obtaining a tissue from the subject; (B) dissociating the tissue to obtain a multicellular cluster, wherein the multicellular cluster comprises the cancer cell; (C) culturing the multicellular cluster on a cellulose sponge; (D) exposing the cultured multicellular cluster to the medication or the treatment regimen; and (E) measuring a first survival rate of the cancer cell before exposing to the medication or the treatment regimen and a second survival rate of the cancer cell after exposing to the medication or the treatment regimen, when the second survival rate is lower than the first survival rate, the method predicts positive effect of the medication or the treatment regimen to the subject.Type: GrantFiled: May 31, 2018Date of Patent: February 23, 2021Assignee: SHANXI PISHON BIOMEDICAL TECHNOLOGY CO., LTDInventors: Chih-Chiang Hsieh, Yen Chang
-
Patent number: 10920215Abstract: The present invention provides a method of modifying a targeted site of a double stranded DNA, including a step of contacting a complex wherein a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a selected double stranded DNA and DNA glycosylase with sufficiently low reactivity with a DNA having an unrelaxed double helix structure (unrelaxed DNA) are bonded, with the double stranded DNA, to convert one or more nucleotides in the targeted site to other one or more nucleotides or delete one or more nucleotides, or insert one or more nucleotides into the targeted site, without cleaving at least one strand of the double stranded DNA in the targeted site.Type: GrantFiled: November 2, 2015Date of Patent: February 16, 2021Assignee: National University Corporation Kobe UniversityInventors: Keiji Nishida, Akihiko Kondo
-
Patent number: 10829787Abstract: Provided herein are compositions and methods useful, inter alia, for the delivery of ribonucleoprotein complexes (e.g., Cas9/guide RNA complexes) into cells. The compositions and methods provided herein are particularly useful for the delivery of ribonucleoprotein complexes into pluripotent cells and lymphatic cells.Type: GrantFiled: October 14, 2016Date of Patent: November 10, 2020Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: Xin Yu, Xiquan Liang, Xavier de Mollerat du Jeu, Robert Jason Potter
-
Patent number: 10799568Abstract: The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g. cancer, by adenoviral vectors which have been coated by polypeptides causing peptide-specific immune response. Also the present invention relates to a method of coating adenoviral vectors by specific peptides as well as to a method of identifying those peptides suitable for coating the capsid of an adenoviral vector.Type: GrantFiled: May 18, 2015Date of Patent: October 13, 2020Assignee: VALO THERAPEUTICS OYInventors: Vincenzo Cerullo, Markus Vähä-Koskela, Mari Hirvinen, Cristian Capasso
-
Patent number: 10793924Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: GrantFiled: June 2, 2017Date of Patent: October 6, 2020Assignee: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Patent number: 10744198Abstract: Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites).Type: GrantFiled: May 10, 2017Date of Patent: August 18, 2020Assignee: Najit Technologies, Inc.Inventors: Ian J. Amanna, Elizabeth A. Poore
-
Patent number: 10745715Abstract: The present invention relates to a producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors produced by the cell are tagged with the tagging protein, wherein the tagging protein comprises: i) a binding domain which binds to a capture moiety ii) a spacer; and iii) a membrane targeting domain such that, when incorporated a retroviral vector, the tagging protein facilitates purification of the retroviral vector from cellular supernatant via binding of the tagging protein to the capture moiety. The present invention also relates to a retroviral vector comprising such a producer cell-derived tagging protein.Type: GrantFiled: August 28, 2015Date of Patent: August 18, 2020Assignee: UCL BUSINESS LTDInventors: Martin Pulé, Leila Mekkaoui, Gordon Weng-Kit Cheung
-
Patent number: 10696960Abstract: A fusion protein comprising factor VII (FVII) and transferrin according to the present invention has an improved specific activity of FVII compared to existing FVII fusion proteins comprising other fusion partners than transferrin, and thus can be effectively used in a therapy using FVII.Type: GrantFiled: March 25, 2016Date of Patent: June 30, 2020Assignee: TiumBio Co., Ltd.Inventors: In-Young Song, Hun-Taek Kim, Bong-Yong Lee, Mahn-Hoon Park, Ho-Soon Lee, Yun Jung Lim, Ji-Hye Lee, Seo Yeon Son, Min-Sun Kim
-
Patent number: 10676721Abstract: The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.Type: GrantFiled: September 2, 2011Date of Patent: June 9, 2020Assignees: Trustees of Boston University, Massachusetts Institute of TechnologyInventors: James J. Collins, Michael Koeris, Timothy Kuan-Ta Lu, Gregory Stephanopoulos, Christopher Jongsoo Yoon
-
Patent number: 10660943Abstract: Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.Type: GrantFiled: February 7, 2014Date of Patent: May 26, 2020Assignee: The Rockefeller UniversityInventors: David Bikard, Luciano Marraffini
-
Patent number: 10639364Abstract: The present invention belongs to the field of animal health and provides means to study Porcine Reproductive and Respiratory Syndrome (PRRS), a viral disease affecting swine, and for the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of PRRS. In a first consideration, the invention relates to a new PRRS virus variant. and, in a second consideration, to a nucleic acid sequence which comprises the genome of an infectious genotype I (EU) PRRS virus clone. Based on this, new PRRS vaccine candidates with improved properties are provided.Type: GrantFiled: June 1, 2018Date of Patent: May 5, 2020Inventors: Andreas Gallei, Christoph Keller, Erik Schacht, Marieke Herrel
-
Patent number: 10626394Abstract: Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.Type: GrantFiled: October 27, 2017Date of Patent: April 21, 2020Assignee: Massachusetts Institute of TechnologyInventors: Timothy Kuan-Ta Lu, Sebastien Lemire, Andrew C. Yang, Kevin M. Yehl
-
Patent number: 10618947Abstract: The present invention relates to a novel Hepatitis B virus (HBV) and/or Hepatitis D virus (HDV) receptor and its use for the development of cells, cell lines and non-human animals that are susceptible to HBV and/or HDV infection and can be used for immunological studies and/or for the screening of drugs, post-entry restriction factors and host dependency factors. It further relates to the use of the receptor for the identification of compounds useful in the treatment of HBV and/or HDV infection.Type: GrantFiled: November 12, 2013Date of Patent: April 14, 2020Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Stephan Urban, Yi Ni
-
Patent number: 10610552Abstract: A nutrient-germinant composition to aid in spore germination and a method for increased spore germination efficiency. The composition comprises L-amino acids, D-glucose and/or D-fructose, a phosphate buffer, an industrial preservative, and may include bacteria spores or they may be separately combined for germination. The method comprises providing a nutrient-germinant composition and bacteria spores, preferably of one or more Bacillus species, and heating to a preferred elevated temperature range of 41° C. to 44° C. for an incubation period of around 2 to 60 minutes. The nutrient-germinant composition is preferably in a concentrated liquid form that is diluted just prior to initiating the germination/incubation method at the point of use. The method may also include dispensing a germinated spore solution to a point-of-use/consumption, such as animal feed, water, or bedding, or a wastewater system or drain.Type: GrantFiled: April 5, 2017Date of Patent: April 7, 2020Assignee: NCH CorporationInventors: Gabriel F. K. Everett, Charles Greenwald, Judy Pruitt, Amanda Rosmarin, Jordan Church, Daniel Aberle, George Aboagye
-
Patent number: 10588957Abstract: The present invention relates to a method for producing stabilised vaccines, the method comprising: (a) mixing antigens with a solution comprising: (i) chitosan; (ii) at least three different amino acids and/or at least one dipeptide or tripeptide; and (iii) a sugar; and (b) drying the mixture obtained in (a).Type: GrantFiled: October 24, 2014Date of Patent: March 17, 2020Assignee: LEUKOCARE AGInventors: Martin Scholz, Jens Altrichter, Kristina Kemter, Regina Scherliess, Hartwig Steckel
-
Patent number: 10577591Abstract: This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.Type: GrantFiled: June 10, 2016Date of Patent: March 3, 2020Assignee: Mayo Foundation for Medical Education and ResearchInventors: Mark J. Federspiel, Arun Ammayappan, Gennett Pike, Stephen James Russell
-
Patent number: 10577590Abstract: The present invention relates to a novel bacteriophage ?CJ28 (KCCM11466P) and a composition containing the same as an active ingredient. Further, the present invention relates to a method for preventing and/or treating infective diseases caused by enterotoxic Escherichia coli (ETEC) of animals excluding humans by using the composition.Type: GrantFiled: March 13, 2015Date of Patent: March 3, 2020Assignee: CJ CHEILJEDANG CORPORATIONInventors: Eun Mi Shin, Gi Duk Bae, Jae Won Kim
-
Patent number: 10550384Abstract: The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.Type: GrantFiled: February 26, 2014Date of Patent: February 4, 2020Assignee: President and Fellows of Harvard CollegeInventors: George M. Church, Srivatsan Raman, Noah D. Taylor, Jameson Rogers
-
Patent number: 10544399Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.Type: GrantFiled: March 22, 2018Date of Patent: January 28, 2020Assignee: Novavax, Inc.Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
-
Patent number: 10526393Abstract: The present invention relates to a method for promoting virus infection and increasing virus production, by using a cell line having lost Bst2 gene functions and, more specifically, to a method for promoting target virus infection and increasing target virus production, in addition to promoting virus budding and inhibiting host cell apoptosis by removing the Bst2 gene from a cell line having the ability to produce a virus. According to the present invention, the method for promoting target virus infection and increasing target virus production, by using an animal cell line having lost Bst2 gene functions, can improve production yields of a target virus and an antigen protein, and thus can be useful for the preparation of vaccines for treating and preventing viral diseases.Type: GrantFiled: June 2, 2015Date of Patent: January 7, 2020Assignee: IMMUNOMAX CO., LTD.Inventors: Se-Ho Park, Eunbi Yi
-
Patent number: 10494402Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis in mammals and uses thereof are provided.Type: GrantFiled: November 25, 2013Date of Patent: December 3, 2019Assignee: The Regents of the University of CaliforniaInventors: Eva A. Turley, Seyed Bahram Bahrami, Mina J. Bissell
-
Patent number: 10487309Abstract: Methods are generally disclosed for attaching a cell binding motif to a carboxy end of a coat protein of a Tobacco Mosaic Virus particle to form a modified-TMV particle; and attaching a cell to the cell binding motif of the modified-TMV particle. Methods are also disclosed for incorporated virus particles, e.g., TMV virus particles into hydrogels.Type: GrantFiled: February 3, 2017Date of Patent: November 26, 2019Assignee: University of South CarolinaInventors: Qian Wang, Lim Andrew Lee
-
Patent number: 10480010Abstract: The present invention relates to an optimized baculovirus construct useful for the production of virus(-like) particles or viral vectors, in particular viral vectors for gene therapy.Type: GrantFiled: July 27, 2012Date of Patent: November 19, 2019Assignee: GENETHONInventors: Lionel Galibert, Otto-Wilhelm Merten, Monique Van Oers, Christel Riviere
-
Patent number: 10463718Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.Type: GrantFiled: October 14, 2016Date of Patent: November 5, 2019Assignee: BIOMARIN PHARMACEUTICAL INC.Inventors: Peter Cameron Colosi, Amit Nathwani, Jenny McIntosh, Edward Tuddenham
-
Patent number: 10435691Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of filovirus infections. In particular, the present invention relates to a method of treating filovirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one oligonucleotide comprising the sequence as set forth in SEQ ID NO:1 to SEQ ID NO:15.Type: GrantFiled: November 8, 2018Date of Patent: October 8, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE), UNIVERSITÉDE BORDEAUXInventors: Samir Amrane, Jean-Louis Mergny, Amina Bedrat
-
Patent number: 10435669Abstract: The invention relates to the field of microbiology, specifically to a bacteriophage, polypeptide and a corresponding polynucleotide, a nucleic acid molecule and/or vector and/or cell comprising such polynucleotide, a composition comprising said bacteriophage, polypeptide, polynucleotide, construct, vector and/or cell, preferably for preventing, treating or diagnosing contamination with and/or a condition in an individual related to Salmonella. The invention further relates to an antimicrobial composition for medical use or for use as a food additive or as a disinfectant, or for detecting bacteria, preferably in a diagnostic application, wherein said antimicrobial composition comprises a bacteriophage, polypeptide, corresponding polynucleotide, construct and/or vector and/or cell comprising such polypeptide and/or composition according to the present invention.Type: GrantFiled: May 7, 2013Date of Patent: October 8, 2019Assignee: MICREOS B.V.Inventors: Martin Johannes Loessner, Steven Hagens, Albert Johannes Hendrikus Slijkhuis, Jochen Achim Klumpp, Roger Marti
-
Patent number: 10391163Abstract: A vaccine composition is disclosed. The vaccine composition comprises: (a) a therapeutically effective amount of an influenza virus-like particle (VLP) comprising: (i) influenza M1, influenza M2, influenza hemagglutinin (HA), and influenza neuraminidase (NA) proteins; (b) Foot-and-mouth disease virus (FMDV) capsid protein VP3, recombinant FMDV VP3 (rVP3), VP3 peptide, or SUMO VP3; and (c) alum. Also disclosed is use of a vaccine composition according to the invention in the manufacture of a medicament for inducing an immunogenic response in a subject in need thereof.Type: GrantFiled: September 9, 2016Date of Patent: August 27, 2019Assignee: Academia SinicaInventors: Shu-Mei Liang, Pei-Wen Hsiao, Ming-Chu Cheng, Yu-Chih Yang
-
Patent number: 10328109Abstract: Described herein is an adenovirus comprising an AB-loop comprising a targeting motif and methods of making and using the adenovirus. The targeting motif of the adenovirus can selectively bind to a tumor cell. The targeting motif of the adenovirus can selectively bind to cell markers and/or cell surface antigens including, for example, CD 133.Type: GrantFiled: April 24, 2015Date of Patent: June 25, 2019Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventor: Masato Yamamoto
-
Patent number: 10322172Abstract: A live, attenuated HIV vaccine is provided, and methods of making a attenuated HIV vaccine are provided.Type: GrantFiled: February 10, 2015Date of Patent: June 18, 2019Assignee: NUtech VenturesInventors: Jiantao Guo, Qingsheng Li, Wei Niu, Yue Li, Nanxi Wang
-
Patent number: 10316334Abstract: CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.Type: GrantFiled: September 1, 2017Date of Patent: June 11, 2019Assignee: Oregon Health & Science UniversityInventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli
-
Patent number: 10309969Abstract: The present invention relates to a method for constructing an Fv library based on a combination of proteins, a method of screening a desired antibody using the constructed Fv library, an Fv antibody screened by the screening method, and an Fv library constructed by the Fv library construction method. The Fv library of the present invention is based on a combination of proteins so that members thereof can be individually analyzed for their function. Moreover, the Fv library enables a desired Fv antibody to be screened without needing a target antigen preparation. In addition, the protein combination based Fv library makes it possible to significantly reduce the number of protein purification processes to thereby reduce costs and time, compared to conventional DNA-based libraries.Type: GrantFiled: January 24, 2014Date of Patent: June 4, 2019Assignee: AbTLAS CO., LTD.Inventors: Byeong Doo Song, Jee Sun Yun, Song Yi Lee, Hye In Kim, Hyo Jung Choi, Jong Rip Choi
-
Patent number: 10301360Abstract: Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.Type: GrantFiled: February 1, 2017Date of Patent: May 28, 2019Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Benjamin E. Deverman, Paul H. Patterson, Viviana Gradinaru
-
Patent number: RE47768Abstract: The present invention relates to virus growth media that improve the yield of alpha-herpesviruses (e.g., HSV-2) grown in cell cultures. The growth media of the invention include two additives, a disaccharide and a lipid mixture, that can be added to serum-free or serum-enriched growth media to improve the efficiency of virus production. The invention further provides methods of producing alpha-herpesviruses (e.g., HSV-2) in such growth media.Type: GrantFiled: November 4, 2016Date of Patent: December 17, 2019Assignee: Sanofi Pasteur Biologics LLCInventors: Simon Delagrave, Rachid Oubelaid, John Hamberger